Walleye Trading
CRSP icon

Walleye Trading’s CRISPR Therapeutics CRSP Stock Holding History

Walleye Trading’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.45M Sell
51,500
-9,700
-16% -$512K ﹤0.01% 1582
2025
Q4 		$3.21M Sell
61,200
-13,300
-18% -$797K ﹤0.01% 1585
2025
Q3 		$4.83M Sell
74,500
-7,500
-9% -$431K 0.01% 1270
2025
Q2 		$3.99M Buy
82,000
+1,300
+2% +$50.3K 0.01% 1331
2025
Q1 		$2.75M Buy
80,700
+37,500
+87% +$1.59M 0.01% 1431
2024
Q4 		$1.7M Buy
43,200
+25,700
+147% +$1.21M ﹤0.01% 1789
2024
Q3 		$822K Buy
17,500
+7,700
+79% +$391K ﹤0.01% 2223
2024
Q2 		$529K Sell
9,800
-27,600
-74% -$1.6M ﹤0.01% 2467
2024
Q1 		$2.55M Sell
37,400
-75,900
-67% -$5.43M 0.01% 1582
2023
Q4 		$7.09M Buy
113,300
+64,400
+132% +$3.56M 0.02% 1006
2023
Q3 		$2.22M Buy
48,900
+5,900
+14% +$305K 0.01% 1709
2023
Q2 		$2.41M Sell
43,000
-198,900
-82% -$11.3M 0.01% 1511
2023
Q1 		$10.9M Buy
241,900
+129,100
+114% +$6.27M 0.02% 597
2022
Q4 		$4.59M Sell
112,800
-51,300
-31% -$2.72M 0.01% 1130
2022
Q3 		$10.7M Sell
164,100
-500
-0.3% -$36.2K 0.03% 591
2022
Q2 		$10M Buy
164,600
+67,800
+70% +$3.99M 0.03% 610
2022
Q1 		$6.08M Buy
96,800
+78,300
+423% +$4.92M 0.02% 887
2021
Q4 		$1.4M Sell
18,500
-600
-3% -$52.4K ﹤0.01% 1940
2021
Q3 		$2.14M Buy
19,100
+2,300
+14% +$289K 0.01% 1563
2021
Q2 		$2.72M Buy
16,800
+6,900
+70% +$839K 0.01% 1239
2021
Q1 		$1.21M Buy
9,900
+3,700
+60% +$559K 0.01% 1743
2020
Q4 		$949K Buy
6,200
+5,900
+1,967% +$697K ﹤0.01% 2012
2020
Q3 		$25K Sell
300
-1,000
-77% -$88.7K ﹤0.01% 3801
2020
Q2 		$96K Sell
1,300
-5,000
-79% -$292K ﹤0.01% 3535
2020
Q1 		$267K Sell
6,300
-48,300
-88% -$2.49M ﹤0.01% 2375
2019
Q4 		$3.33M Buy
54,600
+10,800
+25% +$590K 0.02% 839
2019
Q3 		$1.79M Buy
43,800
+43,300
+8,660% +$2.07M 0.02% 1139
2019
Q2 		$24K Sell
500
-9,300
-95% -$372K ﹤0.01% 3706
2019
Q1 		$350K Sell
9,800
-15,700
-62% -$543K ﹤0.01% 2566
2018
Q4 		$729K Buy
25,500
+24,900
+4,150% +$866K 0.01% 2076
2018
Q3 		$27K Buy
+600
New +$31.4K ﹤0.01% 4757

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Walleye Trading's CRSP Position: Q1 2026 in Review

Walleye Trading reduced its CRISPR Therapeutics (CRSP) stake by 15% in Q1 2026, selling an estimated $138K and leaving 15,086 shares worth $718K. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

Walleye Trading first reported a position in CRSP in Q4 2018 and has held it in 12 quarters since. The position peaked at $1.7M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Walleye Trading held 15,086 shares of CRISPR Therapeutics worth $718K as of Q1 2026.
  • Walleye Trading sold 2,624 CRISPR Therapeutics shares in Q1 2026, an estimated $138K.
  • CRISPR Therapeutics made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #2353 holding.
  • Walleye Trading first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 12 quarters since.
  • Walleye Trading's CRISPR Therapeutics position peaked at $1.7M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.